New blood filter could improve treatment for autoimmune diseases
NCT ID NCT06382675
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study is testing a new blood filter called the Plasma Filter PX2. It is used in a procedure called therapeutic plasma exchange, which removes harmful substances from the blood of people with autoimmune diseases. About 46 adults will take part, and the study will check if the filter works well in everyday hospital practice. The goal is to see if the filter can complete the planned treatment in most cases.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Plasma Filter PX2 (a device used in therapeutic plasma exchange)
What this could lead to
If successful, this could provide a new, effective option for filtering harmful substances from the blood in people with autoimmune diseases.
What could go wrong
This is a small, early-stage study with no comparison group, so results may not apply to everyone. The filter might not work as well as expected in all patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AUTOIMMUNE DISEASES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Charité-Universitätsmedizin Berlin
RECRUITINGBerlin, State of Berlin, 13353, Germany
Contact Email: •••••@•••••
-
Klinikum Aschaffenburg-Alzenau
RECRUITINGAschaffenburg, Bavaria, 63739, Germany
Contact Email: •••••@•••••
-
Klinikum der Ludwig-Maximilians-Universität München (LMU Klinikum)
RECRUITINGMunich, Bavaria, 81377, Germany
Contact Email: •••••@•••••
-
St. Vincenz Kliniken
RECRUITINGPaderborn, North Rhine-Westphalia, 33098, Germany
Contact Email: •••••@•••••
-
Städtisches Klinikum Braunschweig
RECRUITINGBraunschweig, Lower Saxony, 38126, Germany
Contact Email: •••••@•••••
-
Universitätsklinikum Ulm
RECRUITINGUlm, 89081, Germany
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Universitätsklinikum Würzburg
RECRUITINGWürzburg, 97080, Germany
Contact Phone: •••-•••-•••• Email: •••••@•••••